Circulating microparticle concentrations across acute and chronic cardiovascular disease conditions.

Rian Q Landers-RamosOdessa A AddisonBrock BeamerLeslie I KatzelJacob B BlumenthalShawn RobinsonJames M HagbergSteven J Prior

Published in: Physiological reports (2021)

Our findings provide support for the use of different MP subtypes, specifically CD31+/CD42b- MPs, as a potential biomarker of cardiovascular disease. Importantly, results from this study should be looked at in adjunct to previous MP work in CVD conditions as a way of highlighting the complex interactions of variables such as comorbid conditions and medications on MP concentrations.

Keyphrases

cardiovascular disease
type diabetes
liver failure
drug induced
cardiovascular risk factors
metabolic syndrome